These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15531713)

  • 1. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
    Fagin JA
    J Endocrinol; 2004 Nov; 183(2):249-56. PubMed ID: 15531713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New molecular targeted therapies in thyroid cancer.
    Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
    Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel treatment of medullary thyroid cancer.
    Sugawara M; Geffner DL; Martinez D; Hershman JM
    Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):367-72. PubMed ID: 19633548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting RET for thyroid cancer therapy.
    Lanzi C; Cassinelli G; Nicolini V; Zunino F
    Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of BRAF in thyroid oncogenesis.
    Caronia LM; Phay JE; Shah MH
    Clin Cancer Res; 2011 Dec; 17(24):7511-7. PubMed ID: 21900390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of BRAF mutation in thyroid carcinoma.
    Puxeddu E; Durante C; Avenia N; Filetti S; Russo D
    Trends Endocrinol Metab; 2008; 19(4):138-45. PubMed ID: 18337114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
    Riesco-Eizaguirre G; Santisteban P
    Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
    Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
    Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
    Aller S; Popescu A; Rao S; Morgan E; Gosiengfiao Y
    Pediatr Blood Cancer; 2012 Jan; 58(1):98-100. PubMed ID: 21721105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.
    Couto JP; Prazeres H; Castro P; Lima J; Máximo V; Soares P; Sobrinho-Simões M
    J Clin Pathol; 2009 May; 62(5):414-21. PubMed ID: 19147628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic molecular biology in solid tumors--thyroid gland].
    Faksvåg Haugen DR; Varhaug JE; Akslen LA; Lillehaug JR
    Tidsskr Nor Laegeforen; 1998 May; 118(14):2199-203. PubMed ID: 9656818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy in radioiodine refractory thyroid cancer.
    Pacini F; Brilli L; Marchisotta S
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAY 43-9006 inhibition of oncogenic RET mutants.
    Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
    J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.
    Deshpande HA; Gettinger SN; Sosa JA
    Curr Opin Oncol; 2008 Jan; 20(1):19-24. PubMed ID: 18043252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiation therapy for thyroid cancer.
    Brierley JD; Tsang RW
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):497-509, xi. PubMed ID: 18502339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic causes of the thyroid carcinomas].
    Jindrichová S; Vlcek P; Bendlová B
    Cas Lek Cesk; 2004; 143(10):664-8. PubMed ID: 15584614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies.
    Muzza M; Degl'Innocenti D; Colombo C; Perrino M; Ravasi E; Rossi S; Cirello V; Beck-Peccoz P; Borrello MG; Fugazzola L
    Clin Endocrinol (Oxf); 2010 May; 72(5):702-8. PubMed ID: 20447069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.